World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
56
Citations
45358
World Ranking
2172
National Ranking
1079

Overview

Heidi Greulich is affiliated with the Broad Institute in the United States and has contributed extensively to research in the fields of biochemistry, genetics, molecular biology, and medicine. Their scholarly work encompasses a range of topics chiefly related to molecular biology and oncology, with significant publication output in these domains.

The scientist's research spans several subfields including molecular biology, oncology, pulmonary and respiratory medicine, pharmacology, and cancer research. Specific thematic areas of investigation include lung cancer treatments and mutations, phosphodiesterase function and regulation, signaling pathways in disease, cholinesterase and neurodegenerative diseases, RNA and protein synthesis mechanisms, cancer genomics and diagnostics, and receptor mechanisms and signaling.

Heidi Greulich has published in various scientific venues, with frequent contributions to:

  • Cancer Research
  • Journal of Biological Chemistry
  • Molecular Cancer Therapeutics
  • Cell Chemical Biology
  • Nature Cancer

Notable recent papers authored or co-authored by Heidi Greulich include:

  • "Discovering the anticancer potential of non-oncology drugs by systematic viability profiling," 2020, Nature Cancer
  • "Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase," 2021, Nature Communications
  • "Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death," 2022, Nature Chemical Biology
  • "Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12," 2020, Journal of Biological Chemistry
  • "A Role for RAS in V-CRK Transformation," 2025, PubMed

Their frequent collaborators in research include Matthew Meyerson, Andrew D. Cherniack, Colin W. Garvie, Sooncheol Lee, and Bethany Kaplan.

The collected research and publications cover broad scientific inquiries with an emphasis on cancer biology, molecular mechanisms of drug action, and signaling pathway elucidation, demonstrating a multidisciplinary approach to biomedical research.

Best Publications

  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

    J. Guillermo Paez;Pasi A. Jänne;Pasi A. Jänne;Jeffrey C. Lee;Sean Tracy

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • Somatic mutations affect key pathways in lung adenocarcinoma

    Li Ding;Gad Getz;David A. Wheeler;Elaine R. Mardis

  • The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

    Cai-Hong Yun;Kristen E. Mengwasser;Angela V. Toms;Michele S. Woo

  • Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

    Marcin Imielinski;Alice H. Berger;Alice H. Berger;Peter S. Hammerman;Peter S. Hammerman;Bryan Hernandez

  • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

    D Li;L Ambrogio;L Ambrogio;T Shimamura;S Kubo

  • Characterizing the cancer genome in lung adenocarcinoma

    Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner

  • Structures of Lung Cancer-Derived Egfr Mutants and Inhibitor Complexes: Mechanism of Activation and Insights Into Differential Inhibitor Sensitivity

    Cai-Hong Yun;Titus J. Boggon;Yiqun Li;Michele S. Woo

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • Activating mutations in ALK provide a therapeutic target in neuroblastoma

    Rani E. George;Takaomi Sanda;Megan C. Hanna;Stefan Fröhling

  • Landscape of genomic alterations in cervical carcinomas

    Akinyemi I. Ojesina;Lee Lichtenstein;Samuel S. Freeman;Chandra Sekhar Pedamallu

  • Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

    Trevor J Pugh;Trevor J Pugh;Shyamal Dilhan Weeraratne;Shyamal Dilhan Weeraratne;Tenley C. Archer;Tenley C. Archer;Daniel A. Pomeranz Krummel

  • Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

    Heidi Greulich;Tzu-Hsiu Chen;Tzu-Hsiu Chen;Whei Feng;Whei Feng;Pasi A Jänne;Pasi A Jänne

  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

    Jordi Barretina;Barry S Taylor;Barry S Taylor;Shantanu Banerji;Shantanu Banerji;Alexis H Ramos;Alexis H Ramos

  • Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

    Yoon Jae Cho;Aviad Tsherniak;Pablo Tamayo;Sandro Santagata

  • Integrative genomic approaches identify IKBKE as a breast cancer oncogene.

    Jesse S. Boehm;Jean J. Zhao;Jun Yao;So Young Kim

  • Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.

    Steven M. Corsello;Steven M. Corsello;Rohith T. Nagari;Ryan D. Spangler;Jordan Rossen

  • Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

    Peter S. Hammerman;Martin L. Sos;Alex H. Ramos;Chunxiao Xu

  • Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

    Amit Dutt;Alex H. Ramos;Alex H. Ramos;Peter Seth Hammerman;Craig Harold Mermel;Craig Harold Mermel

  • Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

    Roman K. Thomas;Elizabeth Nickerson;Jan F. Simons;Pasi A. Jänne

Frequent Co-Authors

Matthew Meyerson
Matthew Meyerson Harvard University
William R. Sellers
William R. Sellers Harvard University
Levi A. Garraway
Levi A. Garraway Roche (United States)
Kwok-Kin Wong
Kwok-Kin Wong New York University
Gad Getz
Gad Getz Broad Institute
Rameen Beroukhim
Rameen Beroukhim Harvard University
Roman K. Thomas
Roman K. Thomas University of Cologne
Eric S. Lander
Eric S. Lander Broad Institute
Pasi A. Jänne
Pasi A. Jänne Harvard University
Stacey Gabriel
Stacey Gabriel Broad Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in building on your molecular biology education, several online healthcare degree options are available in the U.S. For those already holding a nursing license, the fastest rn to bsn program online pathways enable many professionals to earn a BSN in as little as 6 months. These accelerated programs are designed for working nurses who want to advance their careers quickly.

For those starting with an associate’s in nursing, asn to fnp programs offer direct bridges to becoming a Family Nurse Practitioner. This provides a streamlined path to advanced degrees and expanded clinical roles. Alternatively, if you have a non-nursing background but want to enter the field, you can explore direct entry msn programs for non nurses online, which are tailored for those seeking a quick transition into nursing at a master’s level.

Choosing the right university is crucial for your career. To compare popular online nursing schools, visit the guide on which school is better snhu vs wgu to review program strengths, flexibility, and outcomes. Exploring these educational pathways can open doors to a variety of advanced roles in molecular biology and healthcare.

Best Scientists Citing Heidi Greulich

Trending Scientists